Aarti Drugs Ltd reported a Q3 net profit of ₹40.5 crore, up 9.5% YoY from ₹37 crore, driven by revenue growth of 8.1% at ₹601.7 crore. EBITDA for the quarter declined 11.8% to ₹54.7 crore, with margins falling to 9% 200 bps; declared an interim dividend of ₹2 per share (20%) for FY26, with February 9, 2026, as the record date.
